Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres
Targeted medications and immunotherapies are being developed to specifically target the pathways involved in tumours. There is limited experience with these new medications and their cutaneous side-effects in the paediatric population. A retrospective study of all paediatric oncological patients tre...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2021-07-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3867
|
| _version_ | 1798018352865607680 |
|---|---|
| author | Ayelet Ollech Michal Yalon Gadi Abebe-Campino Vered Molho-Pessach Eve Finklestein Hodaya Cohen Aviv Barzilai Shani Caspi Shoshana Greenberger |
| author_facet | Ayelet Ollech Michal Yalon Gadi Abebe-Campino Vered Molho-Pessach Eve Finklestein Hodaya Cohen Aviv Barzilai Shani Caspi Shoshana Greenberger |
| author_sort | Ayelet Ollech |
| collection | DOAJ |
| description | Targeted medications and immunotherapies are being developed to specifically target the pathways involved in tumours. There is limited experience with these new medications and their cutaneous side-effects in the paediatric population. A retrospective study of all paediatric oncological patients treated with targeted therapies and immunotherapies between 1 January 2013 and 1 August 2020 was carried out in 2 haemato-oncological referral centres. A total of 103 children were included in the study. The median (interquartile range) age was 13 years (8.4–16.9), male:female ratio 1.5:1, median (interquartile range) follow-up was 7 months (2–18). Fifty (48%) of the children developed cutaneous adverse events. Treatment was discontinued in only 3 (6%) cases and was altered in only (2%) 1 case due to a cutaneous adverse event. When targeted therapies and immunotherapies for tumours in children are used, there is an increased incidence of cutaneous adverse events. Nevertheless, treatment modification or discontinuation due to cutaneous side-effects is rarely needed. |
| first_indexed | 2024-04-11T16:22:36Z |
| format | Article |
| id | doaj.art-cd296dad77354f638574d22d98b236a7 |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-04-11T16:22:36Z |
| publishDate | 2021-07-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-cd296dad77354f638574d22d98b236a72022-12-22T04:14:18ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572021-07-011017adv0050110.2340/00015555-38677011Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral CentresAyelet Ollech0Michal YalonGadi Abebe-CampinoVered Molho-PessachEve FinklesteinHodaya CohenAviv BarzilaiShani CaspiShoshana Greenberger Department of Dermatology, Pediatric Dermatology Service, Sheba Medical Center, Tel-Hashomer, 5262000 Ramat Gan, Israel. E-mail: ayelet.ollech@gmail.com. Targeted medications and immunotherapies are being developed to specifically target the pathways involved in tumours. There is limited experience with these new medications and their cutaneous side-effects in the paediatric population. A retrospective study of all paediatric oncological patients treated with targeted therapies and immunotherapies between 1 January 2013 and 1 August 2020 was carried out in 2 haemato-oncological referral centres. A total of 103 children were included in the study. The median (interquartile range) age was 13 years (8.4–16.9), male:female ratio 1.5:1, median (interquartile range) follow-up was 7 months (2–18). Fifty (48%) of the children developed cutaneous adverse events. Treatment was discontinued in only 3 (6%) cases and was altered in only (2%) 1 case due to a cutaneous adverse event. When targeted therapies and immunotherapies for tumours in children are used, there is an increased incidence of cutaneous adverse events. Nevertheless, treatment modification or discontinuation due to cutaneous side-effects is rarely needed. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3867 drug cutaneous adverse events targeted therapies immunotherapies paediatrics oncology |
| spellingShingle | Ayelet Ollech Michal Yalon Gadi Abebe-Campino Vered Molho-Pessach Eve Finklestein Hodaya Cohen Aviv Barzilai Shani Caspi Shoshana Greenberger Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres Acta Dermato-Venereologica drug cutaneous adverse events targeted therapies immunotherapies paediatrics oncology |
| title | Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres |
| title_full | Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres |
| title_fullStr | Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres |
| title_full_unstemmed | Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres |
| title_short | Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres |
| title_sort | cutaneous adverse events to targeted therapies and immuno therapies in children a retrospective study of 103 patients from two tertiary haemato oncology referral centres |
| topic | drug cutaneous adverse events targeted therapies immunotherapies paediatrics oncology |
| url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3867
|
| work_keys_str_mv | AT ayeletollech cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT michalyalon cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT gadiabebecampino cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT veredmolhopessach cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT evefinklestein cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT hodayacohen cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT avivbarzilai cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT shanicaspi cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres AT shoshanagreenberger cutaneousadverseeventstotargetedtherapiesandimmunotherapiesinchildrenaretrospectivestudyof103patientsfromtwotertiaryhaematooncologyreferralcentres |